NKGen Biotech Korea Co., Ltd.
NKGen Biotech Korea licenses out NK cell therapy patents to NKGen Biotech Inc. and provides immune diagnostic and healthcare products.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2002, NKGen Biotech Korea listed on KOSDAQ in 2015 as an immune diagnostics and immunotherapy healthcare company; it entered court receivership in June 2024 and completed the process in September 2025 with NKGen Biotech, Inc. as the designated acquirer, subsequently adopting its current name. It offers research reagents, the NK Vue® diagnostic kit, and SuperNK, along with various immune-based healthcare products and services including health functional foods for immune management. It has licensed out its patent for an EPB41L5 protein-specific epitope-recognizing antibody to Cellasta Co. (formerly Repurpose Us) for a total of KRW 20 billion, and NK cell therapy patent-related technology to NKGen Biotech, Inc. (formerly NKMAX America) for a total of USD 11 million.
Products & technology
- Research reagents
- NK Vue® KITNK cell activity diagnostic kit
- SuperNKNK cell therapy
Regulatory approvals
data.go.kr5 Korean MFDS device approvals · 2012–2016
- MFDSIVD reagents for general immune test2016-10-18Product approval · Class 2체외 제인 16-759 호
- MFDSTube, blood collecting, sealed, evacuated2015-02-16Product approval · Class 1경인 제신 15-75 호
- MFDSTube, blood collecting, sealed, evacuatedRevoked2014-09-02Product approval · Class 1경인 제신 14-510 호
- MFDSIVD reagents for general immune test2012-10-23Product approval · Class 2체외 제허 12-1357 호
- MFDSTube, blood collecting, sealed, evacuatedRevoked2012-09-17Product approval · Class 1경인 제신 12-309 호
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
Founded 2010, listed on KOSDAQ in 2021, Genesystem develops molecular diagnostic systems, biochips, test kits, and reaction reagents.
KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
KOSDAQ-listed IVD company selling AlzOn and AlzOn+ blood-based oligomeric beta-amyloid tests for Alzheimer's risk assessment.
Established in 2010, listed on KOSDAQ in 2020, QuantaMatrix develops dRAST and QDST antimicrobial susceptibility testing systems.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition